Aston Particle Technologies

Aston Particle Technologies

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $2M

Overview

Aston Particle Technologies is a private, pre-revenue platform company spun out from Aston University in 2016 (founded 2018) to commercialize its proprietary isothermal dry particle coating (iDPC) technology. Its core innovation is a dry, solvent-free, and directly scalable process for coating small molecules and biologics onto carrier particles, addressing key formulation challenges in drug delivery. APT operates as a service and technology provider, supporting partners from pre-clinical development through early-phase manufacturing with its in-house expertise and pilot-scale capabilities. The company is backed by grant funding and investors, positioning itself at the intersection of advanced manufacturing and formulation science.

Drug Delivery

Technology Platform

Patented isothermal dry particle coating (iDPC) technology. A low-shear, solvent-free, one-step process for coating nano/micro particles onto larger carrier particles without heat or mechanical mixing, enabling precise formulations for inhalational, biological, and oral solid dose medicines.

Funding History

2
Total raised:$2M
Seed$1.2M
Grant$800K

Opportunities

The global shift towards continuous manufacturing and sustainable, solvent-free processes creates a strong regulatory and environmental tailwind for iDPC technology.
The growing pipeline of complex biologics and poorly soluble small molecules presents a large addressable market for gentle, precise formulation solutions that can improve stability and performance.

Risk Factors

Key risks include slow adoption by a conservative pharmaceutical industry wary of new manufacturing technologies, and competition from established CDMOs and alternative coating methods.
As an early-stage company, APT also faces execution risks in scaling its process under full GMP and financial risks associated with the long sales cycles typical of pharma services.

Competitive Landscape

APT competes within the niche of advanced particle engineering against other dry coating technology providers and specialized CDMOs. Its primary differentiation is the combination of isothermal (no heat), solvent-free, and directly scalable processing in a single platform, which is particularly compelling for heat- and shear-sensitive biologics. Larger, full-service CDMOs represent both potential competitors and future acquirers or partners.